A

Venlafaxine, an SNRI with a short half-life, is well known to produce a discontinuation (withdrawal) syndrome on abrupt cessation, characterized by anxiety, insomnia and other somatic or neuropsychiatric symptoms; case series and reviews consistently document these reactions [Pinzani et al., 2000, PMID 10763190; Sabljić et al., 2011, PMID 21448114].